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PURPOSE. To determine whether inducing calcification in the trabecular meshwork results in
elevated IOP in living rats. To use this property to create an elevated IOP animal model by
gene transfer of bone morphogenetic protein 2 (BMP2).
METHODS. Calcification was assessed by alizarin red staining in primary human trabecular
meshwork (HTM) cells and alkaline phosphatase (ALP) activity in the angle tissue. Brown
Norway (BN) and Wistar rats were intracamerally injected with Ad5BMP2 (OS) and control
Ad5.CMV-Null (OD). IOPs were taken twice a week and expressed as mean integral pressures.
Morphology was assessed on fixed, paraffin-embedded anterior segments. Retinal ganglion
cells (RGCs) were quantified on retrograde and Brn-3a–labeled flat mounts using MetaMorph
software.
RESULTS. BMP2-treated cells displayed marked increase in calcification. Trabecular meshwork
tissue showed moderate ALP activity at 13 days postinjection. Fifty-four of 55 BN and 15 of 19
Wistar rats displayed significantly elevated IOP. In a representative 29-day experiment, the
integral IOP difference between treated and control eyes was 367.7 6 83 mm Hg-days (P ¼
0.007). Morphological evaluation revealed a well-organized trabecular meshwork tissue,
exhibiting denser matrix in the treated eyes. The Ad5BMP2-treated eye showed 34.4% 6 4.8%
(P ¼ 0.00002) loss of peripheral RGC over controls.
CONCLUSIONS. Gene transfer of the calcification inducer BMP2 gene to the trabecular
meshwork induces elevated IOP in living rats without altering the basic structure of the
tissue. This strategy generates an elevated IOP model in rats that would be useful for
evaluation of glaucoma drugs targeting the outflow pathway.
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Elevated IOP remains the major risk factor for the develop-ment of glaucoma,1,2 an irreversible blindness disease of
high prevalence worldwide.3 Elevated IOP is the result of an
increased resistance of the trabecular meshwork tissue to
aqueous humor outflow. This increased resistance can be
caused by a variety of dysfunctional trabecular meshwork cells
and mechanisms. Functions such as secretion, phagocytosis,
cytoskeletal organization, cell-matrix adhesion, ion channel
transport, signal transduction, proteasome activity, and stiffness
have all been shown to have a role in, and to affect, outflow
facility. It is widely accepted though, that the most common
source of an increase in outflow resistance is the disruption of
the organization of the trabecular meshwork’s extracellular
matrix (ECM).4,5
Based on previous findings from our laboratory,6–8 we have
proposed that the trabecular meshwork undergoes a patholog-
ical calcification process with age6 and that this calcification is
more prevalent in glaucoma specimens than in age-matched
controls.7 The undergoing calcification observed in the
trabecular meshwork has many similarities with the calcifica-
tion exhibited by vascular smooth muscle cells (VSMCs) and
the formation of atherosclerotic plaques,9,10 and appears to be
regulated by many of the same procalcific and anticalcific
genes.6,7 Thus, the trabecular meshwork highly expresses
Matrix Gla (MGP) protein,11 an inhibitor of calcification that
is responsible for protecting calcification of other soft tissues,
such as cartilage, VSMCs, and kidney.9,12 After its synthesis, the
MGP protein experiences a vitamin K–dependent posttransla-
tional modification that results in binding of calcium and a
conformational change. It has been shown in various cell types
(including the trabecular meshwork) that the mechanism by
which MGP inhibits calcification is through the binding of this
activated form of the protein to bone morphogenetic protein 2
(BMP2), a potent inducer of bone formation.13–16
BMP2 belongs to the superfamily of TGFb proteins. BMP2 by
itself has the full potential to initiate bone formation and to
induce the differentiation of multipotent mesenchymal progen-
itor cells to the osteogenic lineage.14,17 Similarly, BMP2 induces
osteogenic-like characteristics in primary human trabecular
meshwork (HTM) cells in vitro.6 Overexpression of the BMP2
gene carried by an adenoviral vector in primary HTM cells
induces alkaline phosphatase (ALP) activity,6 an enzyme that
produces a local increase of free phosphate and contributes to
the formation of calcium phosphate precipitates (hydroxyapa-
tite crystals), which are part of the mineralization process.
Formation of the first crystal occurs in the matrix vesicles, 100-
nm particles that originate by budding of the cellular
membrane and then are released into the extracellular space.
In the ECM, the matrix vesicles release the crystal that gets
deposited on collagen fibrils and continues to grow using the
first hydroxyapatite crystal as a template.18,19
Copyright 2013 The Association for Research in Vision and Ophthalmology, Inc.
www.iovs.org j ISSN: 1552-5783 5441
Putting all these findings together, we hypothesized that
overexpression of an inducer of the calcification gene in the
trabecular meshwork tissue would be sufficient to elevate IOP.
We further reasoned that if elevated IOP were to occur upon
induction of trabecular meshwork calcification, the gene
transfer system could be used to generate feasible hypertensive
animal models without damaging (e.g., scarring or laser
treatment) the trabecular meshwork. The immediate advantag-
es of such a system would include the possibility of using the
model for assaying trabecular meshwork conventional and
gene therapy pharmaceuticals, and the relative ease of creating
elevated IOP/glaucoma animal models using this approach.
There are currently a variety of animal models available for
the study of different types of glaucoma (reviewed recently in
Bouhenni et al.20). Not all of them are adequate for the
evaluation of glaucoma drugs. The current genetic models
usually develop elevated IOP at a late onset and some of them
lack synchronicity.21–24 The spontaneous primary open angle
glaucoma (POAG) beagle dog model develops high IOP at 1 to 2
years of age21 and the recombinants MYOC mutant Y423H and
collagen type 1–deficient mice exhibit high IOP between 5 and 6
months.22,25 The Vav-deficient mice, which lack two of the Rho
GTPases activating factors, exhibit earlier high IOP onset and
late closure of the angle,24 and the systemic pigment dispersion
mice (DBA/2J) exhibit secondary IOP elevation.23 The steroid-
induced models in small and large animals respond well to
glaucoma drugs and most require administration two to three
times per day for the elevated IOP26,27 or the implant of osmotic
mini pumps.28 The recently studied polystyrene microbead
injection model in mice is very promising, with early-onset IOP,
retinal ganglion cell (RGC) damaging, and open angles.29,30
Another series of models are designed to study the effect of the
high IOP insult on RGCs and optic nerve degeneration, but these
are not suitable for trabecular meshwork studies. Of these, the
most widely used, the Morrison model,31 injects saline through
the episcleral veins, induces sclerosis, and irreversibly damages
the functional architecture of the trabecular meshwork. The
Sharma model32 induces elevated IOP by cauterizing two to
three episcleral veins and destroys the trabecular meshwork’s
ability to regulate IOP.
In this study, we used a gene transfer strategy to generate an
ocular hypertensive model in a living animal that does not
damage the trabecular meshwork. We selected the inducer of
calcification gene BMP2 and delivered it intracamerally to rats
in an adenoviral vector. Physiological, molecular, and morpho-
logical characterization of the model indicated its potential use
for testing conventional and gene therapy pharmaceuticals
targeting the trabecular meshwork.
MATERIALS AND METHODS
Primary Culture of HTM Cells
Nonglaucomatous eyes from human donors were obtained
within 40 hours of death from national eye banks (Lions Eye
Bank of Oregon, Portland, OR; National Disease Research
Interchange, Philadelphia, PA; The North Carolina Eye Bank,
Winston-Salem, NC) after signed consent of the patients’
families. One cell line, HTM-109, was generated from the
residual cornea rim after a surgical corneal transplant at the
North Carolina Eye Clinic. All procedures were in accordance
with the tenets of the Declaration of Helsinki. For isolation of
HTM cells, the trabecular meshwork from both eyes of a single
individual were isolated from surrounding tissue by making
incisions both anterior and posterior to the meshwork and
removing it with forceps. The tissue was then cut into small
pieces and treated with 1 mg/mL collagenase type IV
(Worthington, Lakewood, NJ), as described.33 Experiments in
this study were performed with cell lines HTM-41, -47, -49, and
-109 (ages 15–39 years old). Cells were used at passages four to
six. These outflow pathway cultures comprise all cell types
involved in maintaining resistance to flow. That includes cells
from the three distinct regions of the trabecular meshwork
plus cells lining the Schlemm’s canal (SC). Because most of the
cells in these cultures come from the trabecular meshwork,
they are commonly referred to as ‘‘trabecular meshwork cells.’’
Viral Vectors and Infection of HTM Cells
The original Ad5BMP2 adenoviral vector was generously
donated by E.A. Olmstead-Davis (Baylor College of Medicine)
and has been described.34 It contains the full-coding cDNA of
the human BMP2 gene driven by the cytomegalovirus (CMV)
promoter. The Ad5.CMV-Null adenovirus was purchased from
Qbiogene (Montreal, Canada). The Ad5 virus AdhMGP contains
the MGPs cDNA driven by the CMV promoter and was
generated in our laboratory.6 The self-complementary adeno-
associated viral vector scAAV2.GFP contains the enhanced GFP
driven by human CMV promoter.35
All high-titer adenovirus stocks were prepared by propaga-
tion in QBI-HEK 293A cells and purification by double binding
CsCl density centrifugation as described.36,37 The collected
viral CsCl band was desalted with NAP-5 columns (GE
Healthcare, Piscataway, NJ) equilibrated with virus vehicle
(0.01 M Tris, pH 7.4, 1 mM MgCl2, 10% glycerol), aliquoted,
and saved at808C. Viral particles (VPs) were titered either by
measurement of its DNA optical density at 260 nm using the
formula 1 lg of DNA ¼ 2.2 3 1010 particles (early lots), or as
viral genomes (vg)/mL by real-time PCR using the Ad5 custom-
designed fluorescent TaqMan primers/probe (University of
North Carolina pathology core facility). The Ad5 probe uses
the hexon gene Ad5 specific primers forward: 50TAG CAT TTG
CCT TTA CGC CA30 and reverse: 50CGT TTC TAA GCA TGG
CCT CA (gene bank accession number AY601635, nts 20,673–
20,692, and 20,749–20,730, respectively, based on Vora et
al.38) and a TaqMan probe with a FAM fluorophore attached to
the 50 and a tetramethylrhodamine (TAMRA) quencher at the 30
(Fam-50CCC CAT GGC CCA CAA CAC CGC30-Tamra). For this,
viral DNA was extracted from 10 lL purified virus (DNeasy
tissue kit; QIAGEN, Valencia, CA), and amplification reactions
were set in triplicate. A standard curve was generated by
amplifying known copy numbers of a laboratory Ad plasmid
standard and plotting them against their threshold cycle (CT)
values. The number of vg was then determined by correlation
of the CT values of the viral DNA to the standard curve. Viral
infectivity (infectious units [IFU]/mL) was measured with a
rapid titer kit (AdenoX; Clontech, Mountain View, CA), as
described.37 One of the Ad5BMP2 lots was grown at the
University of North Carolina Vector Core facility. Viral lots used
in these studies had concentrations between 5.5 3 1012 and 1.7
3 1010 VP/mL.
For viral infection, HTM cells at the indicated passages were
grown to 70% to 80% confluency, washed twice with PBS, and
exposed to Ad5BMP2 at multiplicity of infection (moi) ranging
from 5000 to 8000 VPs per cell for 1 hour in 1 mL serum-free
medium. After exposure to the virus, serum was added to 2%
fetal bovine serum (FBS) and incubated overnight, and full
medium containing 10% FBS was added the next day.
Incubation continued at 378C, and fresh medium was replaced
every 48 hours.
Alizarin Red Staining and ALP Determination
Infected and uninfected cells at 3 to 5 days postinfection were
washed with PBS and fixed in cold 100% methanol at208C for
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10 minutes. They were then washed with ice-cold distilled
water twice and exposed to fresh 1.5% alizarin red (pH 4.2;
Sigma-Aldrich, St. Louis, MO) for 5 minutes (red-orange shows
positive staining). Subsequently, cells were gently washed with
ice-cold distilled water at least three times and photographed
with a microscope-mounted digital camera (DP70; Olympus,
Center Valley, PA).
ALP activity was determined from tissue extracts and
normalized to genomic DNA. Rat anterior segment tissue strips
from Ad5BMP2- and Ad5.CMV-Null–treated eyes containing the
trabecular meshwork were dissected from the angle area and
stored at808C. Tissues were thawed, homogenized, and lysed
in a sterile glass micro tissue grinder (Micro-All-Glass-Tissue
Grinder; Kimble-Chase, Vineland, NJ) with 200 lL PBS. After
two more freezing/thawing cycles, tissue homogenates were
briefly sonicated and centrifuged. Supernatants were collected
and saved at 808C for the measurement of endogenous ALP
and DNA for normalization. ALP was measured using a
fluorescence substrate system (AttoPhos AP; Promega, Madi-
son, WI) that does not contain an endogenous ALP inhibitor.
Triplicates of 5-lL aliquots were adjusted to 100 lL with PBS
and incubated with 100 lL AttoPhos substrate at room
temperature in a black microlon 96-well plate (Greiner Bio-
One, Monroe, NC) in the dark. A parallel set of incubations was
conducted with different dilutions (from 5 ng to 100 ng) of a
purified ALP enzyme (Clontech) to generate a standard curve.
Controls containing PBS aliquots without enzyme were run in
parallel. Fluorometric values were usually read after 20 minutes
incubation time in a FLUOstar fluorescence plate reader (BMG
Lab Technologies, Durham, NC) with a 430-nm excitation and
555-nm emission filters. ALP accepted readings were from
values falling inside the standard curve. For the DNA relative
quantity, 30 lL from the treated and control tissue extract
supernatants were purified by applying them directly to a
QIAquick Gel extraction kit column (QIAGEN) and elution
with 30 lL of manufacturer’s buffer according to recommen-
dations; 1 lL from treated and untreated samples was then
amplified and hybridized to an 18S TaqMan Probe
(Hs99999901_s1) by real-time PCR (Applied Biosystems
[ABI], Carlsbad, CA). Relative quantities of treated versus
control DNAs were expressed on fold changes (FCs) and
calculated by using the formula 2DCT (DCT is the difference of
the cycles at threshold between treated and control). ALP
fluorescence values of treated and control samples were finally
obtained by subtracting the ALP value from PBS controls and
normalized by the FC of their DNA.
Experimental Animals
All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of North
Carolina and were conducted in accordance with the tenets of
the Declaration of Helsinki and the ARVO statement on the Use
of Animals in Ophthalmic Research. Rat strains were either
male brown Norway (BN) (300–400 g) retired breeders or male
Wistar (100–150 g) and were purchased from Charles River
Laboratories (Wilmington, MA). All animals were housed in
standard 12-hour cycle lighting with food and water provided
ad libitum.
Intraocular Administration of Recombinant Viral
Vectors
After a brief isoflurane inhalation, each rat was anesthetized by
intraperitoneal injection of a ketamine/xylazine/acepromazine
(Butler Schein, Columbus, OH) cocktail to achieve concentra-
tions of 50 mg/kg (ketamine), 5 mg/kg (xylazine), and 1 mg/kg
(acepromazine), respectively. While resting on its side, the rat
was placed under a surgical microscope (Wild Heerbrugg M5A
stereo microscope; Adlon Instruments, St. Louis, MO) with the
head propped up in a holder and eyes directed upward. The
corneas were anesthetized with one drop of 0.5% tetracaine
(Bausch & Lomb, Tampa, FL). For the intracameral vector
delivery, a 30-gauge needle was inserted through the superior
cornea at the limbus with the bevel up, to gently reach the
center of the anterior chamber. The needle device consisted of
the tip of a 30-gauge needle, broken at the middle, connected
to one end of intramedic-polyethylene tubing (PE-10; BD/Clay
Adams, Franklin Lakes, NJ). The remaining half of the needle,
plus the hub, was attached at the other end of the tubing and
then connected to a dispenser (Gilmont micrometer syringe;
Thermo Fisher Scientific, Waltham, MA). The tubing was
partially filled with a colored glycerol driving solution to allow
aspiration of 4 to 5 lL of the viral sample. Inside the tubing, the
driving solution was kept separated by 3 to 4 cm from the
sample at all times. When the needle was inside the anterior
chamber, the sample was delivered by the assistant over 30
seconds and fluid entry monitored by direct visualization
through the operating microscope (Wild Heerbrugg M5A
stereo microscope; Adlon Instruments). The needle was left
in place for 1 to 2 minutes and withdrawn gradually to
minimize leaking. Topical antibiotic ointment (neomycin 3.5
mg/g, polymyxin B 10,000 U/g, and bacitracin 400 U/g; Akorn,
Lake Forest, IL) was placed on the eyes, and the animals were
returned to their cages, resting on absorbent paper for
recovery.
RNA Extraction, Reverse Transcription, and Real-
Time PCR
HTM cells either uninfected or Ad5BMP2-infected, were
scraped from 3-cm tissue culture dishes with 350 lL guanidine
thiocyanate buffer (RLT; QIAGEN) at 3 days postinfection. Total
RNA was extracted by loading the solution onto a column
(QIAshredder; QIAGEN) and continued by the use of a kit with
on-column RNase-free DNase digestion (RNeasy Mini kit;
QIAGEN) in accordance with the manufacturer’s recommen-
dations. Purified RNA was eluted in 30 lL RNase-free water and
concentration measured with a spectrophotometer (NanoDrop
ND-100; Thermo Fisher Scientific). Recoveries were between
13.4 and 18.6 lg per dish.
Rat angle tissue strips containing the trabecular mesh-
work were excised from globes immersed for 1 week in
RNAlater (Ambion, Austin, TX). Globes were dissected at the
equator and the posterior segment discarded. Anterior
segments were cleaned of the iris and lens, the ciliary body
was carefully folded back, and two parallel cuts were made at
both sides of the trabecular meshwork using an Optimal
microsurgery blade (Wilson Ophthalmics, Mustang, OK). The
tissue strip was placed in a sterile glass micro-tissue grinder
(Kimble-Kontes), homogenized with 350 lL guanidine
thiocyanate buffer, and loaded onto a column (QIAshredder;
QIAGEN). Treated and untreated eyes from two rats were
pooled and RNA extraction was continued as indicated above
for the human cells. Recoveries were between 1.1 and 2.4 lg
RNA per extraction.
Reverse transcription (RT) reactions were conducted in a
25-lL total volume of proprietary RT buffer containing random
primers, dNTPs, and 62.5 U of enzyme with RNase inhibitor
(MultiScribe MuLV RT; High Capacity cDNA kit; ABI),
according to manufacturer’s recommendations (258C for 10
minutes, 378C for 2 hours, 858C for 5 minutes). The total
amount of RNA used in each of the RTs was 1 lg for the human
cells and 0.46 lg for the rat angle tissue.
Fluorescently labeled TaqMan probe/primer sets for human
BMP2, collagen type I alpha1 (COL1A1), osteoglycin (OGN),
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runt-related transcription factor 2 (RUNX2), osteocalcin
(BGLAP), bone sialoprotein 2 (IBSP), and 18S, as well as those
for rat COL1A1, RUNX2, BGLAP, IBSP, and MGP were
purchased from the TaqMan Gene Expression Assays collection
(ABI). The human BMP2 (Hs00154192_m1) corresponded to
sequences from exons 2 and 3, the human COL1A1
(Hs00164004_m1) and BGLAP (Hs01587814_g1) correspond-
ed to sequences from exons 1 and 2, the human OGN
(Hs00247901_m1) corresponded to sequences from exons 3
and 4, the human RUNX2 (Hs001047973_m1) corresponded
to sequences from exons 5 and 6, and the human IBSP
(Hs00173720_m1) corresponded to sequences from exons 4
and 5. The rat COL1A1, RUNX2, BGLAP, IBSP, and MGP
(Rn001463848_m1, Rn01512298_m1, Rn00566386_g1,
Rn00561414_m1, Rn00563463_m1) probes corresponded to
sequences from exons 1 and 1, 2 and 3, 3 and 4, 4 and 5, 1 and
2, respectively; the 18S RNA probe corresponded to sequences
surrounding position nucleotide 609 (Hs99999901_s1). Reac-
tions were performed in triplicate 20-lL aliquots using TaqMan
Universal PCR Master mix No AmpErase UNG (ABI), run on an
ABI 7500 Real-Time PCR System, and analyzed by 7500 System
SDS v.2.0.4 software (ABI). Experiments were repeated at least
twice. Relative quantification (RQ) values between treated and
untreated samples were expressed in FC and calculated by the
formula 2DDCT, where CT is the cycle at threshold and DCT is
CT of the assayed gene minus CT of the endogenous control
(18S). DDCT is the DCT of the normalized assayed gene in the
treated sample minus the DCT of the same gene in the
untreated one (calibrator). Because of the high abundance of
the 18S ribosomal RNA used as the endogenous control, and in
order to get a linear amplification, RT reactions from treated
and untreated samples were diluted 104 times prior to their
hybridization to the 18S TaqMan probe.
Measurement of IOP
IOPs were measured unmasked in sedated rats once or twice
a week. At the beginning of the study, IOPs were recorded
with a calibrated handheld tonometer (Tonopen XL; Mentor,
Norwell, MA). Midway through the study, IOPs were
measured by the use of the rebound tonometer. The rebound
tonometer used for approximately half of the rat groups was
one of the prototypes developed at Mount Sinai School of
Medicine (New York, NY) and generously provided to us by
Thomas Mittag and John Danias.39,40 The IOP of the
remaining groups was measured using the TonoLab (Colonial
Medical Supply, Franconia, NH) equipped with a foot pedal.
The rats were lightly anesthetized with the described
isoflurane/intraperitoneal cocktail at half-dose and with an
eye drop of 0.5% tetracaine. To take IOP measurements, the
rats were positioned with the visual axis horizontal to the
probes. For the tonopen, IOPs were obtained as the average
of 10 consecutive measurements for each eye. For the
prototype rebound tonometer, the probe was held at a
distance between 1 and 4 mm and five consecutive readings
(arbitrary units that correlate to IOP) were obtained by
pressing the foot pedal connected to the probe power
supply. Only mean values with an SD (expressed as
percentage of the mean) less than 5% were accepted. This
tonometer was calibrated on rats at the same ages as those
used in the experiments (before and 3.5 months after
injection) by ex vivo cannulation and manometric readings
as described.40 IOP-correlated values were obtained by
creating a logarithmic calibration curve with the tonometer
and manometric values, and then obtaining the a and b
constant values in the formula Y¼aLn(X)b, where X is the
correlated IOP and Y is the tonometer’s measurement. The
calibration curves had correlation coefficients of 0.98 and
0.96, respectively. For the Tonolab, IOP measurements were
conducted following manufacturer’s recommendations. Inte-
gral IOP (cumulative pressure received by each rat on the
entire duration of the experiment) was calculated using the
Area Under the Curve (AUC) tool of the GraphPad Prism 5
software (GraphPad Software, Inc., La Jolla CA).
Histology and Fluorescence Histochemistry
Rats’ eyes were enucleated immediately after euthanization
and immersed either in fresh 4% paraformaldehyde (PFA) in
PBS for 30 minutes or in RNAlater (Ambion) for 5 to 7 days at
48C. For histological evaluations, the eyes were subsequently
dissected at the equator, their lens removed, and wedge-
shaped specimens containing the anterior chamber angle
region with the trabecular meshwork were postfixed for
morphology or GFP fluorescence. To assess morphology,
wedges were immersed in 4% PFA/2.5% glutaraldehyde at
room temperature for at least 24 hours followed by
immersion in 0.1 M cacodylic acid, pH 7.35, overnight.
Specimens were then rinsed in distilled water for 10 minutes
and transferred to 70% ethanol for delivery to the University
of North Carolina Histology Core for paraffin embedding.
Meridional 5-lm sections were mounted on microscope
slides (Superfrost Plus; Thermo Fisher Scientific) and stained
with hematoxylin and eosin. To evaluate GFP fluorescence,
tissue wedges were postimmersed in fresh 4% PFA from 4 to
18 hours, then consecutively washed in 10% sucrose (6
hours) and 30% sucrose (overnight) and frozen in optimal
cutting temperature medium (Tissue-Tek; Sakura Finetek,
Torrance, CA) in liquid nitrogen. Meridional 10-lm sections
were mounted on Superfrost Plus microscope slides (Thermo
Fisher Scientific) with Fluoromount G (SouthernBiotech,
Birmingham, AL) and GFP visualized with a fluorescence
microscope (model IX71; Olympus). Images were captured
with a digital camera (DP70; Olympus) and accompanying
software. Digital images were arranged with image-analysis
software (Photoshop CS; Adobe Photoshop, Mountain View,
CA). Quantification of fluorescence intensities in treated and
control images was carried out using MetaMorph for
Olympus digital imaging software (Olympus). In each
experiment, exposure for nonsaturated conditions was first
determined using the brightest tissue section and then using
the obtained exposure value in all specimens of the same
experiment. Total intensity of the area of the trabecular
meshwork was measured in the green channel by tracing the
region in the brightest image and transferring it to the
comparison images using the transfer region and region
statistics tools of the program.
RGCs Retrograde Labeling and Brn-3a
Immunohistochemistry
Loss of RGCs was assessed in labeled flat mounts by two
procedures: retrograde labeling and immunocytochemistry.
For the retrograde labeling, rats were deeply anesthetized by
intramuscular injections of a ketamine/xylazine cocktail to a
dose of 70 mg/kg ketamine and 30 mg/kg xylazine. Rats were
then immobilized on a stereotaxic apparatus (KOPF, Tujunga,
CA), their head fur shaved, and exposed skin infiltrated with
1% bupivacaine (Hospira, Inc., Lake Forest, IL). A 1- to 2-cm
incision was made to expose the dorsal surface of the skull
and sutures. With the help of a caliper, microinjection points
were drawn on the skull 6 mm posterior to bregma and 2.0
mm lateral to the sagittal suture. Openings were made
through the skull at the marked sites to expose the superior
colliculus using a Micro Drill system (World Precision
Instruments, Sarasota, FL). A 5-lL Hamilton 65RN syringe,
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equipped with a 2-inch 30G RN NDL point 4 needle
(Hamilton, Reno, NV) was loaded with a 3% Dil dye solution
(Molecular Probes/Life Technologies, Carlsbad, CA) (dis-
solved in dimethyl sulfoxide–ethanol 1:1) and placed in the
stereotaxic frame. Using the stereotaxic’s micromanipulator
(KOPF), the needle was lowered 4.5 mm to deliver 1.5 lL of
the tracer. The needle was kept in place for 10 minutes,
slowly withdrawn, antibiotic ointment (erythromycin, 5 mg/
g; E. Fougera & Co., Melville, NY) applied and the skin
incision sutured with 2-0 silk, nonabsorbable suture (Oasis,
Mettawa, IL). Rats were placed on top of deltaphase
isothermal pads at 378C (Braintree Scientific, Braintree, MA)
for recovery. Seven days after tracer labeling, rats’ eyes were
enucleated immediately after euthanization and immersed in
fresh 4% PFA for 1 hour with a corneal puncture. Eyes were
then opened at the limbus, lens and ciliary body removed,
and retinal cups rinsed with PBS and treated with 20 lg/mL
hyaluronidase (Sigma-Aldrich) for 30 minutes at room
temperature. Consecutively, retinal cups were postfixed for
30 minutes and washed in PBS overnight. The next morning,
retinas were dissected from the underlying sclera/choroid,
flattened by four radial cuts, mounted vitreal side up on
Superfrost Plus slides (Thermo Fisher Scientific), and cover-
slipped with a drop of antifade mounting medium containing
0.1 mg/mL p-phenylenediamine (Sigma-Aldrich) in 90%
glycerol/PBS, pH 8.0 (PPD). Images were taken in an
Olympus XI71 fluorescence microscope equipped with an
Olympus DP70 digital camera and software. For each retina,
images were taken from 20, 320 fields (0.394 mm2) located at
0.5 mm from the periphery (two per quadrant). Automated
cells counts in each field were obtained on the gray scale
mode using MetaMorph software for Olympus (Olympus) and
using the same threshold value. For each individual retina,
the total count of surviving RGC neurons was obtained by
averaging the eight counts for each retina. Results are
expressed in percentage of RGC loss in the Ad5BMP2-treated
eyes versus the Ad5.CMV-Null-control. The two groups in
each experiment were analyzed for differences using the
Student’s paired t-test.
For the immunohistochemistry procedure, rats were
either immersed in 4% PFA for 1 hour as indicated above,
or perfused through the heart using a gravity system (In Vivo
Perfusion System, 70 cm high; AutoMate Scientific, San
Francisco, CA) following the manufacturer’s recommenda-
tions. Briefly, rats were deeply anesthetized with intraperi-
toneal injection of 100 to 400 mg/kg of euthasol (Butler
Schein) and their chest cavities opened. A 20G 3 3/4-inch
scalp vein set (EXEL International, Los Angeles, CA) was
inserted into the left ventricle and approximately 150 mL
0.9% NaCl was perfused through the circulatory system after
making a slit on the right atrium to allow perfusion. Perfusion
continued with 400 to 600 mL 4% PFA made in 0.1 M
phosphate buffer pH 7.2 until the rat’s body was stiff. Eyes
were then immediately enucleated and treated like above for
flat mounting on Superfrost Plus slides (Thermo Fisher
Scientific). Subsequently, a hydrophobic ring was drawn
around the retina using a Liquid Blocker super pap-pen
(Newcomer Supply, Middleton, WI), retinas were rinsed with
PBS/0.5% Triton X-100 and permeabilized at 808C for 15
minutes. Alternatively, the nonperfused, hyaluronidased/
postfixed retinas were separated from the sclera/choroid,
kept in solution in 24 wells for all immunohistochemistry
steps, and flat mounted after the last wash. For this, after
thawing them at room temperature, in-well retinas were
washed and blocked with 2% donkey serum/PBS/0.5% Triton
X-100 for 1 hour. Retinas were then incubated with goat
antihuman Brn-3a antibody (1:550, sc-31984; Santa Cruz
Biotechnologies, Santa Cruz, CA) overnight followed by an
additional 2 hours with donkey antigoat Alexa Fluor 568
(1:550; Molecular Probes/Life Technologies). All antibody
solutions were made in 2% donkey serum/PBS/0.5% Triton X-
100, and three washes (PBS/0.5% Triton X-100) were
performed between incubation steps. Slides with retinal flat
mounts were briefly dried on the slide warmer and cover-
slipped with a drop of Fluoromount G (SouthernBiotech).
Images were taken with either a Zeiss LSM 510 Meta confocal
(Carl Zeiss Group, Oberkochen, Germany) or an Olympus
XI71 microscope equipped with its own digital camera
software (LSM 510 for the confocal and DP70 for the
Olympus). For each retina, images were taken from eight,
320 fields (0.212 and 0.394 mm2, respectively) at half field
from the periphery. Quantification was subsequently per-
formed as indicated above.
Conventional Glaucoma Drugs
The prostaglandin formulation used was 0.01% lumigan
(Allergan, Inc., Irvine, CA). A 50-lL drop of the formulation
was administered twice a day to the OD of conscious rat by
holding them down gently at the bottom of the cage. Control
eyes received PBS drops from a clean 50-lL dispenser eye drop
bottle or no drops.
Statistical Analysis
Average values are expressed as mean 6 SE. The significance
of experimental changes was analyzed using Student’s t-test as
either paired or unpaired data. For the calculation of P values,
all technical replicates from all biological replicates were used.
A value of 0.05 was chosen as the level of significance. The
power of the experiments was determined using the GraphPad
StatMate2 software (GraphPad Software, Inc.).
RESULTS
Overexpression of BMP2 Induces Calcification in
Primary HTM Cells
We have previously shown6 that infection of primary HTM
cells with a recombinant adenovirus carrying the BMP2
transgene (Ad5BMP2)34 increased the activity of ALP, an
established marker of early osteogenic differentiation.41,42
Here we examined the morphology of the HTM cells by
staining them with alizarin red, also a widely used calcification
marker. BMP2-infected cells from all cell lines examined in this
study (n ¼ 4) showed marked calcification morphology when
stained with alizarin red. The cells from infected dishes began
to retract 2 days postinfection and aggregated in elongated
structures that stained positive for calcification (Fig. 1A1).
Young, noninfected cells showed no aggregates, and exhibited
normal cell morphology (Fig. 1A2). The characteristic aggre-
gated cell organization had the appearance of a small tissue
explant and was more pronounced at specific conditions such
as later postinfection times and in HTM cell lines that have
been aged in culture for more than 4 weeks (Fig. 1A3). Old,
HTM noninfected cells also calcified, but formed the more
typical calcification round nodules (Fig. 1A4) previously
described for VSMCs.6
Extracted RNAs from treated and untreated cells were
analyzed for induction of expression of calcification gene
markers by TaqMan PCR. When normalized to 18S cDNA,
transgene human BMP2 cDNA levels were increased 22,904 6
4398-fold (P ¼ 0.007) in the infected cells over those treated
with vehicle, confirming high delivery and expression of the
BMP2 transgene. This BMP2 overexpression induced human
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collagen type 1 (COL1A1) 41 6 8.6-fold (P¼0.01), while genes
for OGN and transcription factor RUNX2 were slightly reduced
(1.5 6 0.37-fold, P ¼ 0.002, and 1.74 6 0.22-fold, P ¼
0.0002, respectively) (Fig. 1B). The expression of additional
calcification markers integrin-binding protein IBSP and BGLAP
were also assayed in a different experiment. In this experi-
ment, where BMP2 was induced 334,191 6 91,654-fold (P ¼
0.02), expression of BGLAP was not changed (1.3 6 0.21-fold,
P¼ 0.18), while that of IBSP was induced 371 6 114-fold (P¼
0.03) (Fig. 1C).
FIGURE 1. Effect of overexpressing BMP2 in primary HTM cells. Cells at passage 5 and 70% to 80% confluency were infected with Ad5BMP2 at moi
between 5000 and 8000 VP/cell and harvested 3 to 5 days postinfection. (A) Cells stained with alizarin red. (1) corresponds to a representative
infected well at 3 days postinfection, whereas (2) represents a parallel uninfected dish. A second HTM cell line was aged in culture for 2 months,
infected with Ad5BMP2, and stained at 5 days postinfection (3). (4) represents a parallel dish of 2 months aged in culture uninfected cells. (B, C)
TaqMan analysis of the RNA extracted from HTM-infected and untreated controls at 3 days postinfection, in two different cell lines. Results are
expressed in FC of the infected versus the untreated and normalized to 18S. Human TaqMan probes were BMP2, COL1A1, OGN, RUNX2, IBSP,
BGLAP, human 18S. *P  0.05. Overexpression of BMP2 induced calcification in HTM cells as well as expression of COL1A1 and IBSP markers.
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Single Intracameral Injection of Ad5BMP2 Delivers
Human BMP2 mRNA to the Cells of the Rat Angle
To first test the positive delivery of the transgene to the rat’s
angle, four BN rats were injected with 4 to 5 lL of 1.3 3 1012
VP/mL stocks of Ad5BMP2 (OS) and Ad5.CMV-Null (OD) viral
vectors. Thirteen days after injection, RNA was harvested from
two of the rat’s pooled angle tissues and assayed in triplicate
for the presence of human BMP2 (transgene) by TaqMan PCR.
The human BMP2 gene expression was undetected in the OD
control eyes and thus assigned a CT of 40 for calculations.
When normalized to 18S, expression of human BMP2 cDNA in
the Ad5BMP2-treated eye (OS) versus that of Ad5.CMV-Null-
treated controls (OD) was 112 6 19-fold (P¼0.03). In a similar
trend as in the human cells, overexpression of human BMP2
protein in the angle of the living rat induced the expression of
the osteogenic differentiation marker COL1A1 2.9 6 0.6-fold
over that of the control eye (P¼0.04) but at this time period, it
did not change the expression of RUNX2 (1.03 6 0.4, P¼ 0.9).
At these levels of human BMP2 overexpression, the calcifica-
tion markers IBSP and BGLAP were not induced (0.75 6 0.3, P
¼ 0.5 and 0.84 6 0.2, P ¼ 0.4, respectively) (Fig. 2A).
The experiment was repeated two additional times using
two rats’ pooled angle tissues from a different group of Wistar
rats injected with 4 to 5 lL from a different 5.5 3 1012 VP/mL
Ad5BMP2 viral stock versus two pooled tissues of näıve rats.
RNA was harvested at 12 days postinjection. Each time, three
independent cDNA RT reactions were assayed in triplicate by
TaqMan PCR using the same probes indicated above normal-
ized by 18S. Results were very similar, but FC changes were
more pronounced, most likely due to the use of a higher-titer
viral stock. Although human BMP2 expression was undetected
in the näıve rats (assigned a CT value of 40 for calculations), its
expression exhibited an increase of 1918 6 148-fold (P ¼ 2 3
109) in the Ad5BMP2-injected eyes. At these high levels of
BMP2 overexpression, COL1A1 was induced 86.9 6 8.6-fold
(P¼ 2 3 107) over the näıve eye, RUNX2 was increased 7.0 6
0.9-fold (P¼ 0.00003) and IBSP was induced 70 6 17-fold (P¼
0.0003). The BGLAP gene remained, as above, uninduced (1.8
6 0.4, P ¼ 0.07) (Fig. 2B).
Together, these results indicate that calcification markers are
induced by a dose-dependent overexpression of BMP2 and
suggest that calcification could be one of the causes of the
elevated IOP observed in the Ad5BMP2-injected eyes. Induction
of some of the markers, such as bone sialoprotein 2 (IBSP),
seems to appear only when the BMP2 cDNA levels are higher.
Single Intracameral Injection of Ad5BMP2 Induces
Sustained Elevated IOP in Rats
A total of 74 rats (55 BN and 19 Wistar) were injected in the
anterior chamber of one eye with 8 3 107 to 2.7 3 1010 VP of
Ad5BMP2 (treated) in different studies. The contralateral eye
was similarly injected with the same range of VP of Ad5.CMV-
Null (control). Elevated IOP of the treated versus the control
was observed in 54 of the 55 BN and in 15 of the 19 Wistar rats.
The pressures were elevated at approximately 7 days
postinjection and sustained for up to 6 to 7 weeks. To
maximize transgene delivery, maximum intracameral injection
volumes (4–5 lL) were always used and the extent of elevated
IOP seemed to be affected by the number of VP injected and,
to some extent, by the rat strain. BN rats experienced a higher
IOP elevation in the treated eye than Wistar rats, with a
TonoLab (Colonial Medical Supply) mean difference between
IOP values at 4 weeks ([treated  baseline]  [control 
baseline]) of 25.2 6 2.4 (n¼ 15, P¼ 1 3 1010). In the original
experiments, Wistar rats exhibit a lower but highly significant
elevation at the same time period with DIOP values of 3.5 6
0.6 (n ¼ 13, P ¼ 1 3 107). However, when a higher
concentration viral stock was used, the Wistar rats’ DIOP
increased and the difference between the two strains
diminished (see the Initial Responsiveness to Conventional
and Gene Therapy Glaucoma Drugs section).
Figure 3 shows two representative experimental groups of
BN rats where IOP values were obtained using either the
tonopen (Figs. 3A, 3C) or the TonoLab (Colonial Medical
Supply) (Figs. 3B, 3D). In the tonopen experiment (Fig. 3A),
absolute IOP values for the Ad5.CMV-Null control and
Ad5BMP2-treated eyes were plotted at baseline, 7, 16, 28, 36,
42, and 48 days (n ¼ 10 rats). The mean absolute IOPs of the
Ad5BMP2-injected eyes were 24.4 6 0.3 mm Hg at baseline
and 42.3 6 1.9 mm Hg at 48 days postinjection (n ¼ 10, P ¼
0.000005), whereas those of the Ad5.CMV-Null–injected eyes
FIGURE 2. Delivery of human BMP2 cDNA to the living rat
iridocorneal angle by Ad5BMP2 intracameral injection: its effect on
expression of calcification genes. Tissue strips from the angle region
containing the trabecular meshwork were dissected at 12 to 13 days
postinjection and their RNA extracted for TaqMan analyses. Results are
expressed in FC of the Ad5BMP2-injected rats versus controls and
normalized to 18S. (A) OS eyes of BN rats (n¼ 4) were injected with 4
3 109 VP of Ad5BMP2 and compared with their OD receiving the same
VPs of Ad5.CMV-Null. (B) OS eyes from Wistar rats (n ¼ 4) were
injected with 2 3 1010 VP of Ad5BMP2 and compared with OD and OS
of Wistar Näıve rats (n ¼ 2). TaqMan reactions were performed in
triplicate, each from 2 to 4 independent RT reactions. TaqMan probes
were human BMP2, rat COL1A1, rat RUNX2, rat IBSP, rat BGLAP,
human 18S. *P  0.05. Transgene human BMP2 was efficiently
delivered to the rat iridocorneal angle. At higher concentrations,
overexpression of human BMP2 induced rat COL1A1, RUNX2, and
IBSP calcification markers in the living rat.
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were 25.9 6 0.4 mm Hg at baseline and 25.4 6 1.0, also at 48
days (n¼10, P¼0.70). Thus, at the last time period of 48 days,
the mean DIOP elevation from baseline was 17.9 6 1.9 mm Hg
in the Ad5BMP2-injected eyes and 0.5 6 1.1 mm Hg for the
contralateral control (n ¼ 10, P ¼ 0.000005 and P ¼ 0.70,
respectively). Considering the whole study period, the animal
with the highest DIOP from baseline (peak DIOP baseline) in
the treated eye had an IOP elevation of 33.0 mm Hg at 24 days
(full range of all animals 12.0 to 33.0 mm Hg). For the mean
IOP difference between treated and contralateral control eyes
(peak IOP difference), the highest value was 18.4 6 1.7 mm
Hg (n ¼ 10, P ¼ 0.000002) at 48 days. The animal with the
highest IOP difference between its treated and contralateral
control eyes had an IOP elevation of 33.0 mm Hg at 24 days
(full range of all animals 16.0–33.0 mm Hg). The mean integral
IOP (defined as the mean of the cumulative IOP that each
animal received for the duration of the experiment) was
1886.6 6 58.3 mm Hg-days for the Ad5BMP2-injected eyes and
1403.0 6 31.5 mm Hg-days for the Ad5.CMV-Null–injected
eyes, which results in an integral IOP difference of 483.6 6
FIGURE 3. Rat elevated IOP induced by overexpression of human BMP2 cDNA. Two representative BN rat groups were injected with 5 3 109 to 9 3
107 VP Ad5BMP2 (OS) and 7 3 109 to 9 3 108 VP Ad5.CMV-Null (OD), respectively. IOP was measured using a tonopen (A, C) or a TonoLab rebound
tonometer (B, D). (A) IOP absolute values of treated and control eyes from the tonopen group (n ¼ 10) during 48 hours after injection. Mean
baseline IOP of all eyes was 25.3 6 0.3 mm Hg. (B) IOP absolute values of treated and control eyes from the TonoLab group (n¼ 6) during 29 days
after injection. Mean baseline IOP of all eyes was 9.9 6 0.1 mm Hg. *P  0.05 at the last time points (A, B). (C, D) AUC plots of the mean IOPs of
treated (broken line) and control eyes (continuous line) from the tonopen (C) and TonoLab (D) groups. The integral IOP differences are depicted
in gray. (E) Summary table of the numeric values of measurements and calculations of IOP differences between treated and controls in both groups,
P  0.007. Delivery and overexpression of the human BMP2 transgene to the iridocorneal of the living rat induces significant elevation of IOP when
compared with controls.
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61.6 mm Hg-days (n ¼ 10, P ¼ 0.00003). The highest integral
IOP difference in a single animal was 758 mm Hg-days.
In the TonoLab (Colonial Medical Supply) experiment (Fig.
3B), absolute IOP values for the Ad5.CMV-Null control and
Ad5BMP2-treated eyes were plotted at baseline and 8, 18, 24,
and 29 days (n¼ 6 rats). Of the seven rats injected, one did not
show elevated pressure and was excluded from the study. The
mean absolute IOPs of the Ad5BMP2-injected eyes were 10.0 6
0.3 mm Hg at baseline and 26.2 6 3.6 mm Hg at 29 days
postinjection (n¼ 6, P¼ 0.005), whereas those of the Ad5.CMV-
Null–injected eyes were 9.9 6 0.3 mm Hg at baseline and 9.6 6
0.5 at 29 days (n¼ 6, P¼ 0.67). Thus, at the same time period,
the mean DIOP elevation from baseline was 16.1 6 3.4 mm Hg
in the Ad5BMP2-injected eyes and 0.3 6 0.6 mm Hg for the
contralateral control (n ¼ 6, P ¼ 0.005 and P ¼ 0.67,
respectively). Considering the whole study period, the animal
with the highest DIOP from baseline (peak DIOP baseline) in the
treated eye had an IOP elevation of 27.2 mm Hg at 29 days (full
range of all animals 11.2 to 27.2 mm Hg). For the IOP difference
between treated and contralateral control eyes, the highest
value (peak IOP difference) was 20.2 6 4.3 mm Hg (n¼ 6, P¼
0.006) at 29 days. The animal with the highest IOP difference
between its treated and contralateral control eyes had an IOP
elevation of 29.3 mm Hg at 29 days (full range of all animals at all
time periods 10.5 to 29.3 mm Hg). The mean integral IOP was
634.0 6 86.8 mm Hg-days for the Ad5BMP2-injected eyes and
266.3 6 8.6 mm Hg-days for the Ad5.CMV-Null–injected eyes,
which results in an integral IOP difference of 367.7 6 83.3 mm
Hg-days (n¼6, P¼0.007). The highest integral IOP difference in
a single animal was 626.8 mm Hg-days.
Clinical Observations and Trabecular Meshwork
Morphology of Rats Injected With Ad5BMP2
As we reported before, intracameral injections of recombinant
adenoviruses are well tolerated by rats.35 After intracameral
injections of Ad5BMP2 and Ad5.CMV-Null viruses there were
no clinical signs of inflammatory reaction, redness, or tearing.
However, approximately 30% of the eyes from the BN rats
injected with Ad5BMP2 exhibited an enlarged globe and a
moderate corneal opacity. The opacity correlated with the
enlarged globe that, in turn, correlated with those individual
rats showing the highest increase in IOP values of the group.
Such opacity was not observed in the eyes of Wistar rats.
The morphology of the trabecular meshwork injected with
Ad5BMP2 was assessed versus that of the contralateral eye
injected with Ad5.CMV-Null. Although some variation among
individual rats could be observed, in all cases the trabecular
meshwork was well preserved and the angle was open.
Representative images from different experiments with Wistar
and BN rats are shown in Figure 4 and Supplementary Figure
S1, respectively. Most morphologies of the Ad5BMP2-injected
FIGURE 4. Morphology of the rat trabecular meshwork after gene transfer of BMP2. Representative images of the eye angle region from a group of
Wistar rats injected with 5 3 109 VP of Ad5BMP2 (OS, left) and 1 3 109 Ad5.CMV-Null (OD, right) and killed at 77 days postinjections. Anterior
segment wedges were fixed in 4% paraformaldehyde/2.5% glutaraldehyde, embedded in paraffin, and 5-lm sections stained with hematoxylin and
eosin. Original magnification: 3100 (top), 3200 (bottom). TM, trabecular meshwork; SC, Schlemm’s canal. Ad5BMP2-treated eye shows an open
angle and a well-conserved trabecular meshwork structure with a denser ECM than the contralateral Ad5.CMV-Null control.
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eye could be easily distinguished from the Ad5.CMV-Null
contralateral eye. Although both eyes showed an intact
trabecular meshwork structure, the region underneath the SC
appeared to be more dense in the BMP2-overexpressing rats,
with less empty spaces in between the beams, as if it they were
filled with more ECM (Fig. 4 and Supplementary Fig. S1, left
panels). At this light microscopy resolution, we could not
observe a strong correlation between a given morphology and
the levels of elevated IOP. Rats experiencing a moderate
elevation in IOP also showed an increased density, which often
did not appear to be much different from the density observed
in the higher IOP rats. Although not physically counted, the
number of trabecular meshwork cells observed in both treated
and control eyes appeared to be maintained (Fig. 4, Supple-
mentary Fig. S1).
Evaluation of RGCs
Because prolonged elevated IOP induces damage to the RGC
layer, we tested whether the pressure induced by BMP2
overexpression affected the survival of these cells in two
groups of BN rats at 29 to 28 days post–viral injection.
Evaluation of RGCs was performed by different methods. In the
first group, four rats from the TonoLab (Colonial Medical
Supply) experiment (Fig. 3) were injected with 3% DiI into the
superior colliculus at 29 days post-Ad5BMP2 injections. Three
of four rats showed significant RGC loss (Fig. 5A). In the
peripheral region (0.5 mm for the periphery), the percent
average RGC loss in the BMP2-treated eyes versus the Null-
treated eyes was 34.3% 6 4.8% (P ¼ 0.00002).
In the second BN group (n ¼ 9 rats, 28 days), RGCs were
labeled using Brn-3a immunohistochemistry rather than the
more invasive superior colliculus dye injection. Sixteen retina
flat mounts from eight of the nine rats were suitable for
counting. Of the 16, 7 retinas from Ad5BMP2-injected eyes
experienced a significant peripheral RGC loss when compared
with the 7 from their contralateral eyes injected with
Ad5.CMV-Null. The average RGC loss in the BMP2-treated
eyes versus the Null-treated was 31.0% 6 4.8% (n ¼ 7, P ¼
0.0006) (Fig. 5B). In a supporting Brn-3a immunohistochem-
istry experiment with Wistar rats, where the IOP elevation of
Ad5BMP2-injected eyes was smaller due to a lower titer viral
FIGURE 5. Effect of BMP2-induced elevated IOP on RGC survival. (A) BN rats (n¼ 3) injected with 7 3 107 VP of Ad5BMP2 (OS) and 7 3 108 VP of
Ad5.CMV-Null (OD) were retrograde labeled with 3% Dil solution at 29 days postinjection. (B) Retinas of BN rats (n¼7) injected with 2.7 3 1010 VP
of Ad5BMP2 (OS) and 7 3 108 VP of Ad5.CMV-Null (OD) were flat mounted and stained with Brn-3a at 28 days postinjection. Left: percentage of Dil-
(A) or Brn-3a-labeled (B) RGC cell loss in the treated eyes normalized to untreated. Right: representative fluorescence photomicrographs of treated
and untreated flat-mounted retinas taken from the peripheral retina. The number of positive cells was obtained from eight peripheral fields per each
flat-mounted retina using MetaMorph software. The number of positive RGC cells was significantly reduced in the elevated IOP-BMP2 treated eyes.
*P  0.006.
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stock, we saw a smaller, albeit significant, RGC loss in the
periphery of the retina 16.3% 6 1.5% (P¼ 0.02) (n¼ 3). In this
group, the average IOP cumulative difference between the
Ad5BMP2- and Ad5.CMV-Null–treated eyes was 133 mm Hg-
days, whereas the cumulative difference in the BN experiments
above were 367 and 729 mm Hg-days, respectively.
Altogether, these results indicate that at 4 weeks, the
elevated IOP induced by overexpression of BMP2 is not only a
result of TonoLab (Colonial Medical Supply) readings but it has,
as expected, a physiological effect on the RGC.
Alkaline Phosphatase Activity on the Rat Angle
Tissue
The levels of the calcification marker ALP were measured in
two groups of BN rats at 23 and 28 days postinjection,
respectively. In the first group (n ¼ 5), one eye was injected
with 2 3 1010 VP of Ad5BMP2, while the contralateral was left
uninjected. Elevated IOP was observed at 7 days in all injected
eyes and averaged an increase over baseline of 37 6 5.5 mm
Hg at 23 days, when the experiment was terminated. Angle
tissue strips were homogenized for the extraction of ALP and
DNA, as indicated in the Methods section. After normalizing for
the amount of genomic DNA in each tissue strip, we found that
the levels of ALP in the Ad5BMP2-injected versus uninjected
tissue varied, and were elevated in only two of the five rats.
The values ranged between an increased 189% ALP in the eye
of one viral-injected rat (P¼ 0.00002) to a reduction of 56.6%
in another rat (P¼ 0.00008). In the second group of rats (n¼
5), the IOP of the Ad5BMP2-injected eyes had an increase over
baseline of 31.1 6 1.1 mm Hg at 28 days, when the rats were
killed. Although the variation trend continued, the higher
levels of normalized ALP in the BMP2 eyes were observed in a
greater proportion of rats. Thus, of the five, ALP was high in
three rats (77.7% 6 7.4%, P ¼ 0.0005), low in one of them
(3.4%, P ¼ 0.32), and reduced 41.3% in the fifth rat (P ¼
0.0007).
The lower levels of ALP in the eyes of some rats injected
with Ad5BMP2 were unexpected and would appear to
contradict the established effect of the bone inducer BMP2.
At this time, we interpret this finding as perhaps due to the
potential presence of high concentration of the BMP2-inhibitor
MGP in the trabecular meshwork tissue, which would induce a
counteracting effect and lead to a minimal, undetected
calcification. Indeed, the measured relative levels of rat MGP
cDNA in the angle strips of näıve rats showed a MGP
expression of 174.9 6 40.6-fold when compared with the
low-expressing rat BGLAP gene (P ¼ 0.002). The undetected
calcification level seen in several rats was nevertheless
sufficient to induce elevated IOP. To this effect, a recent study
shows that the proximity between MGP and BMP2 proteins
plays a role in ossification.43 One could speculate that the lack
of control of which trabecular meshwork regions are
transduced by Ad5BMP2 after intracameral injection could
result in different distribution that would be more or less
affected by the presence of MGP.
Initial Responsiveness to Conventional and Gene
Therapy Glaucoma Drugs
To initiate validating the model as a potential tool for
evaluating conventional and/or gene drugs, we performed
two types of experiments. For the testing of conventional
drugs, we used two Wistar rat groups. In one group (n ¼ 6),
four rats were injected with Ad5BMP2 in both eyes, treated
with the drug in one eye and left the contralateral eyes
untreated to serve as controls. The remaining two rats were
injected with Ad5BMP2 in the OS and left untreated, while
their OD was uninjected and treated with PBS drops. At 13
days postinjection, the ODs of the first four rats were treated
with one drop of lumigan 0.01% twice a day for 3.5
consecutive days, while their OS remained untreated. The
average IOP of the lumigan-treated eyes before Ad5BMP2
injections was 9.0 6 0.4 mm Hg and showed an increase of
19.6 6 3.8 mm Hg at 9 days postinjection (n ¼ 4, P ¼ 0.01).
After lumigan administration (measured 2 hours post–last
administration, total 16 days post–viral injection) the IOP
showed an increase from baseline of only 8.9 6 4.6 mm Hg,
which corresponds to a reduction of 55.1% (P ¼ 0.07) from
IOP values before the treatment. Six days after lumigan
withdrawal, the IOP showed an increase from baseline of
12.4 6 3.7 mm Hg, indicating a wearing off of the drug
effect. For the untreated controls, the OS Ad5BMP2-injected,
non–lumigan-treated eyes (n ¼ 6) had an average IOP of 8.9
6 0.2 mm Hg before viral injections and experienced an
increase from baseline of 15.8 6 2.5 mm Hg (9 days
postinjection, P ¼ 0.001), 12.6 6 1.5 mm Hg (16 days, P ¼
0.0005), and 15.5 6 1.8 mm Hg (22 days, P ¼ 0.0004). The
two additional OD eyes that had been uninjected and treated
with PBS drops for 3.5 days showed average IOPs of 9.6 6
0.4 mm Hg at baseline, 9.3 6 0.3 mm Hg at 9 days, 8.5 6
0.2 mm Hg at 16 days, and 9.8 6 1.5 mm Hg at 21 days.
Following a similar design, in the second group (n¼5), four
rats were injected with Ad5BMP2 in both eyes. Then, the OD
was treated with the drug in OD while the contralateral
untreated OS served as a control. As above, an additional rat
was injected with Ad5BMP2 in only one eye (OS) while the OD
received PBS drops to assess contralateral effect. The average
IOP of the OD lumigan-treated group before Ad5BMP2
injections was 9.0 6 0.3 mm Hg and showed an increase
from baseline of 30.0 6 1.3 mm Hg at 7 days postinjection (n¼
4, P ¼ 0.0002). Lumigan administration started at 8 days
postinjection and IOP was measured 2 hours post–last
administration at day 12, when the experiment was terminat-
ed. After the lumigan treatment, IOP values showed an
increase from baseline of 3.8 6 2.0 mm Hg, corresponding
to a reduction of 87.3% (P ¼ 0.0008) from IOP values before
the treatment (Fig. 6A). The OS, Ad5BMP2-injected, non–
lumigan-treated eyes (n ¼ 5) had IOPs of 9.4 6 0.3 mm Hg
(baseline) and exhibited increases from baseline of 29 6 0.9
mm Hg (7 days, P¼0.000006) and 31.4 6 1.1 mm Hg (12 days,
P ¼ 0.00001) (Fig. 6B). An additional virus uninjected/
untreated eye had IOPs of 10.5 mm Hg at baseline, 10.7 mm
Hg at 7 days and 10.0 mm Hg at 12 days (all uninjected/
untreated eyes in Fig. 6C). Altogether, these results suggest that
the BMP2-induced elevation IOP model holds good promise for
the evaluation of conventional trabecular meshwork drugs.
Initial experiments with gene therapy drugs showed that
pretreatment of the Ad5BMP2-injected eye with an adenovirus
of the same serotype 6 days before the high IOP induction
precluded the Ad5BMP2-induced IOP elevation (n ¼ 8, half of
them pretreated with Ad5.CMV-Null and half with AdhMGP,6
both serotype 5). Using a reporter gene, we then observed that
postinjection of the Ad5 serotype with a scAAV.GFP serotype 2,
at 29 days allowed expression of the reporter gene (n¼4). At 1
week post–reporter injection, the quantification of fluores-
cence in a traced trabecular meshwork area of 111,268 pixels
minus background showed an average of 15.8 fluorescence
intensity units per pixel (FIU/pix). In contrast, postinjection
with a virus of the same serotype, Ad5.GFP, showed an average
of 6.2 FIU/pix under the same conditions (n¼ 3). In a different
experiment, postinjection of the same serotype at 7 days
showed 5.2 FIU/pix (traced area 161,777 pixels minus
background) (n¼ 2). However, coinjection of the Ad5 reporter
with Ad5BMP2 allowed expression of the GFP transgene (36.0
FIU/pix on a trabecular meshwork–traced area 166,980 pixels
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minus background). Fluorescence quantification of the report-
er transgene without previous Ad5BMP2 or Ad5.CMV-Null
injections was not available. These results indicate that
serotypes would play an important role when assaying viral
gene therapy drugs in this model, and that the gene therapy
drugs will work best on viral IOP models generated by a
different serotype.
DISCUSSION
Convenient, small animal models to evaluate trabecular
meshwork drugs for the treatment of hypertension and
glaucoma are scarce.20 Most of them consist of genetically
modified mice that develop elevated IOP at 5 to 8 months of
age, often in an asynchronous mode, which makes it difficult to
study drug evaluation. One of the more promising recent
advances is the microbead model, in which beads, a bead/
viscoelastic combination, or paramagnetic polystyrene micro-
spheres are injected into the anterior chamber of mice and rats
to clog the outflow pathway.29,30,44,45 Since our laboratory has
developed transgene delivery to the trabecular meshwork
using viral vectors,35–37,46 we reasoned that an additional
animal model of elevated IOP could be generated by gene
transfer to the outflow tissue. We further hypothesized that
overexpression of a secreted gene in the trabecular meshwork
that would contribute to the formation of a denser ECM, would
most likely result in elevated IOP. In our search for a candidate
ECM-IOP inducer gene we came to rely on our previous
findings that revealed the presence of an ongoing calcification
process in the trabecular meshwork.6 For this study, we
selected BMP2, one of the most potent calcification inducer
genes.47 We found that a single intracameral dose of the
Ad5BMP2 vector to the trabecular meshwork of living rats was
sufficient to induce elevation of IOP.
In contrast to most existing models, the elevation of IOP
had a rapid and uniform onset and could be observed at 7 days
postinjection. In addition, the elevated IOP was maintained for
at least 4 to 6 weeks after injection of the virus, which provides
an extended period of time for the assay of glaucoma drugs. As
expected, the extent of elevated IOP is dependent of the
number of VP injected, thus the titer and age of the viral stock
need to be taken into account. Rats seem to be an ideal animal
for this IOP model. Their anterior segment morphology is
clearly defined and exhibits a well-formed SC. Of the two rat
species studied, BN had a somewhat higher response than the
Wistar rats and both strains tolerate adenovirus intraocular
injection without developing a clinical inflammatory reaction.
BN rats had already been identified as a preferred small animal
to conduct IOP/RGC studies due to their gentle nature and
protruding eyes, which makes conducting intraocular injec-
tions and taking IOP measurement relatively easy.31 The only
drawback we found in this BMP2 model was that some of the
BN rats exhibiting higher delta pressures developed a moderate
corneal opacity, a secondary effect that would preclude an
intraocular evaluation by current optical coherence tomogra-
phy technology in this rat strain. Except for that exclusion, all
other evaluation parameters, such as frequent IOP measure-
ments and molecular, histological, immunohistochemistry, and
RGC survival end points, can be performed adequately and
together can provide a complete assessment of the assaying
drug. The corneal opacity was not observed in the Wistar rats.
It is important to note that this rat model was generated
using a human BMP2 cDNA. Although the identification of the
transgene would be more difficult because of hybridization
probes cross-reacting with the endogenous gene, it is possible
that the IOP effect would be further improved by using the
homologous gene.
An important characteristic of this model is that the
architecture and cellular organization of the trabecular
meshwork is preserved. Morphology images showed that the
angle remains open with an apparent increase of ECM between
the layers of the trabecular meshwork tissue. As a conse-
quence, this model could be used to evaluate glaucoma drugs
that target the trabecular meshwork. To this effect, our first
experiments using lumigan drops were very encouraging and
FIGURE 6. Representative experiment of the evaluation of the BMP2
model with a prostaglandin-derived glaucoma drug. Eyes of Wistar rats
were injected with 2 31010 Ad5BMP2 VP (n¼9) or left uninjected (n¼
3). At 8 days postinjection, eyes were (A) treated twice a day for 3.5
days with one drop of 0.01% lumigan (n¼ 4), or (B) left untreated (no
drops, n ¼ 5). (C) Uninjected eyes treated with PBS (n ¼ 3). IPO
measurements are expressed as DIOP from baseline (A, B) or absolute
values (C). *P  0.05. Rats with BMP2-induced elevated IOP exhibit a
significant IOP reduction on treatment with a conventional glaucoma
drug.
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showed an IOP reduction of 55% to 87% after instillation of eye
drops twice a day for 3.5 days.
The mechanism of action for the increased IOP in this rat
model is not yet fully determined. BMP2 is a potent inducer of
calcification/bone formation and recombinant BMP2 adminis-
trations have been approved by the Food and Drug Adminis-
tration for the treatment of bone fracture repair. Previously we
have shown that HTM cells transduced with the same
Ad5BMP2 vector and overexpressing human BMP2 had
increased levels of the calcification marker ALP, and that this
effect was reversed by co-transduction with MGP.6 Here we
show that a similar transduction in these cells induces dramatic
morphological calcification changes. The cells of the dish
retracted from each other and aggregated forming structures
that stained deeply with alizarin red. Under these conditions,
the calcification markers’ transcripts, collagen type 1 and bone
sialoprotein, assayed by real-time PCR, were significantly
upregulated, whereas those encoding for OGN, RUNX2, and
BGLAP were not. This indicates that the morphological
calcification observed in the trabecular meshwork cells is
influenced more by the higher induction of COL1A1 and IBSP
levels, and that in these cells calcification can occur without an
increased presence of OGN, transcription factor RUNX2, or
BGLAP. COL1A1 is an integral component of the calcified
matrix vesicles,8 as well as a key component of the
extracellular scaffold of the trabecular meshwork. IBSP binds
to collagen and is a major structural protein of the bone matrix.
Under noninduced conditions, IBSP is barely detected in the
trabecular meshwork which is perhaps the reason why its new
presence provokes the calcification changes.
In the trabecular meshwork of the tissue of the living rat,
the increased levels of the calcification marker ALP varied with
the individual rats. A potential explanation for this result could
be that the living trabecular meshwork tissue expresses high
levels of MGP, which is considerably downregulated in tissue
culture (Borrás T, unpublished observations, 2008). The
mechanism of action of the inhibitor of calcification MGP has
been shown to be that of binding and sequestering BMP2.6 As
it occurred in the cells, there was a significant induction of
COL1A1 and, at a higher concentration of BMP2, there was
also significant induction of IBSP and to a lesser extent,
RUNX2. Thus, at this time, we believe that even if the
biochemical detection of calcification in the living animal is
small, it appears nevertheless to be sufficient to cause an
elevation of IOP.
We cannot discard the possibility though, that only a
segment of the calcification pathway, or a different
alternative pathway elicited by overexpression of BMP2 has
a major influence in obstructing the outflow pathway and
triggering elevated IOP. For example, it could be possible
that the overexpression of COL1A1, a key component of the
trabecular meshwork ECM found to be elevated in glau-
comatous conditions,48 would by itself elevate IOP. The
combination of this with other induced pathways could
enhance the outcome. Thus, it has been extensively shown
that there is crosstalk between BMP2 and the WNT
pathways.49 The canonical WNT/bcatenin pathway is
involved in the commitment of mesenchymal cells to
osteoblasts and has been implicated in the pathogenesis of
bone diseases.50 The WNT/bcatenin pathway is crucial for
BMP2 to induce bone formation51 and osteogenic differen-
tiation of dental follicle cells induced by stimulation with
BMP2 is suppressed by WNT/bcatenin pathway inhibitors.49
But in this and other studies, it has been observed that
during the osteogenic differentiation, BMP2 also induces
expression of the WNT antagonist WIF1, suggesting the
presence of a negative feedback mechanism to regulate
osteogenesis.49 Interestingly, the WNT/bcatenin pathway has
been shown to be present in the trabecular meshwork and
implicated in IOP regulation.52–55 The WNT antagonist
secreted frizzled-related protein 1 (sFRP1) was upregulated
by elevated IOP and in glaucomatous samples,52,53 and its
overexpression in the trabecular meshwork by adenoviral
delivery reduced outflow facility in perfused human organ
cultures. The interaction between the two pathways is
complex and it would be interesting to find whether sFRP1
would enhance or abrogate the BMP2 induction of elevated
IOP.
The BMP2 elevated IOP model described here responded
well to prostaglandin analog–derived drugs. All eight rats
tested exhibited an IOP reduction after 3.5 days, twice a day
administration of lumigan 0.01%. The prostaglandin drug
group’s site of action is the uveoscleral and conventional
outflow pathways, thus it makes sense that this model, based
on the modification of the ECM of the outflow tissue, would
respond well to outflow targeting drugs. As a result, our
findings place this model on a nice niche for the assay of
trabecular meshwork conventional drugs. Experiments to test
other types of conventional glaucoma drugs, such as b-
blockers, are ongoing. In the present study, we also showed
that evaluation of gene therapy drugs in this model is possible,
albeit certain considerations are needed. Because the model is
based on the injection with a virus of a given serotype,
potentially therapeutic transgenes would need to be inserted in
viral vectors of a different serotype from the one used to
generate the model. Such experiments are in progress and
initial results have revealed expression of a serotype 2 reporter
following injection of a serotype 5 virus.
In addition to the advantages mentioned above, these
gene transfer models provide a new generic, comprehensive
platform to develop elevated IOP models, in more than one
species and with more than one viral vector. The require-
ments for their development, in time and cost, are favorable
to those of generating transgenic animals. Since our first
presentation of this model (Buie LK, et al. IOVS 2009;50:AR-
VO E-Abstract 4841), an IOP model using an adenovirus
carrying the active form of TGFb2 or connective tissue
growth factor CTNF has been developed successfully in rats
and mice.56–58 At the current time, no large animal models
have been reported. Our first collaborating trials using the
same vector in large animals have not yet been successful
(Kaufman PL, Weber AJ, Borrás T, unpublished results, 2011)
due in great part to the high inflammatory response of large
animals to high concentration of adenoviruses.59 Neverthe-
less, the same concept could be used by carrying the
transgene in a lower inflammatory response vector, such as
scAAV or lentiviruses. Adenoviruses have great advantages
for rats, including the shorter expression time of the
transgene, which could benefit in the evaluation process.
Another advantage as usage of viral vectors increases is that
many of these viral reagents carrying relative common genes
(such as BMP2) are available commercially and/or at
universities’ vector core facilities.
In summary, we are presenting an alternative modality to
generate elevated IOP models in living animals by gene
transfer. Our first model using a single intracameral adminis-
tration of the calcification inducer BMP2 by an Ad5 vector
proved to be very efficient in rats. The characteristics of this
model, simplicity, short time of onset, uniformity, and,
especially, that of keeping an intact trabecular meshwork,
provide a unique opportunity for the evaluation of trabecular
meshwork-targeted glaucoma drugs. Finally, although mecha-
nisms are not yet fully elucidated, the ocular hypertension
observed in these rats on overexpression of BMP2 suggests
that there is an association between induction of calcification
and elevation of IOP.
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13. Böstrom K, Tsao D, Shen S, Wang Y, Demer LL. Matrix GLA
protein modulates differentiation induced by bone morpho-
genetic protein-2 in C3H10T1/2 cells. J Biol Chem. 2001;276:
14044–14052.
14. Ducy P, Karsenty G. The family of bone morphogenetic
proteins. Kidney Int. 2000;57:2207–2214.
15. Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of
the binding of matrix Gla protein (MGP) to bone morphogenetic
protein-2 (BMP-2). Thromb Haemost. 2000;84:1039–1044.
16. Nakagawa Y, Ikeda K, Akakabe Y, et al. Paracrine osteogenic
signals via bone morphogenetic protein-2 accelerate the
atherosclerotic intimal calcification in vivo. Arterioscler
Thromb Vasc Biol. 2010;30:1908–1915.
17. Riley EH, Lane JM, Urist MR, Lyons KM, Lieberman JR. Bone
morphogenetic protein-2: biology and applications. Clin
Orthop Relat Res. 1996;(324):39–46.
18. Anderson HC. Matrix vesicles and calcification. Curr Rheu-
matol Rep. 2003;5:222–226.
19. Yang H, Curinga G, Giachelli CM. Elevated extracellular
calcium levels induce smooth muscle cell matrix mineraliza-
tion in vitro. Kidney Int. 2004;66:2293–2299.
20. Bouhenni RA, Dunmire J, Sewell A, Edward DP. Animal models
of glaucoma. J Biomed Biotechnol. 2012;2012:692609.
21. Gelatt KN, Gum GG, Gwin RM, Bromberg NM, Merideth RE,
Samuelson DA. Primary open angle glaucoma: inherited
primary open angle glaucoma in the beagle. Am J Pathol.
1981;102:292–295.
22. Zode GS, Kuehn MH, Nishimura DY, et al. Reduction of ER
stress via a chemical chaperone prevents disease phenotypes
in a mouse model of primary open angle glaucoma. J Clin
Invest. 2011;121:3542–3553.
23. John SW, Smith RS, Savinova OV, et al. Essential iris atrophy,
pigment dispersion, and glaucoma in DBA/2J mice. Invest
Ophthalmol Vis Sci. 1998;39:951–962.
24. Fujikawa K, Iwata T, Inoue K, et al. VAV2 and VAV3 as
candidate disease genes for spontaneous glaucoma in mice
and humans. PLoS One. 2010;5:e9050.
25. Aihara M, Lindsey JD, Weinreb RN. Ocular hypertension in
mice with a targeted type I collagen mutation. Invest
Ophthalmol Vis Sci. 2003;44:1581–1585.
26. Sawaguchi K, Nakamura Y, Nakamura Y, Sakai H, Sawaguchi S.
Myocilin gene expression in the trabecular meshwork of rats
in a steroid-induced ocular hypertension model. Ophthalmic
Res. 2005;37:235–242.
27. Gerometta R, Podos SM, Danias J, Candia OA. Steroid-induced
ocular hypertension in normal sheep. Invest Ophthalmol Vis
Sci. 2009;50:669–673.
28. Whitlock NA, McKnight B, Corcoran KN, Rodriguez LA, Rice
DS. Increased intraocular pressure in mice treated with
dexamethasone. Invest Ophthalmol Vis Sci. 2010;51:6496–
6503.
29. Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The
microbead occlusion model: a paradigm for induced ocular
hypertension in rats and mice. Invest Ophthalmol Vis Sci.
2010;51:207–216.
30. Yang Q, Cho KS, Chen H, et al. Microbead-induced ocular
hypertensive mouse model for screening and testing of
aqueous production suppressants for glaucoma. Invest Oph-
thalmol Vis Sci. 2012;53:3733–3741.
31. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK,
Johnson EC. A rat model of chronic pressure-induced optic
nerve damage. Exp Eye Res. 1997;64:85–96.
32. Shareef SR, Garcia-Valenzuela E, Salierno A, Walsh J, Sharma
SC. Chronic ocular hypertension following episcleral venous
occlusion in rats. Exp Eye Res. 1995;61:379–382.
33. Vittitow J, Borrás T. Genes expressed in the human trabecular
meshwork during pressure-induced homeostatic response. J
Cell Physiol. 2004;201:126–137.
34. Olmsted EA, Blum JS, Rill D, et al. Adenovirus-mediated BMP2
expression in human bone marrow stromal cells. J Cell
Biochem. 2001;82:11–21.
35. Buie LK, Rasmussen CA, Porterfield EC, et al. Self-comple-
mentary AAV virus (scAAV) safe and long-term gene transfer in
the trabecular meshwork of living rats and monkeys. Invest
Ophthalmol Vis Sci. 2010;51:236–248.
36. Borrás T, Rowlette LL, Erzurum SC, Epstein DL. Adenoviral
reporter gene transfer to the human trabecular meshwork
does not alter aqueous humor outflow. Relevance for potential
gene therapy of glaucoma. Gene Ther. 1999;6:515–524.
Elevated IOP Model in Rats by Gene Transfer IOVS j August 2013 j Vol. 54 j No. 8 j 5454
37. Spiga MG, Borrás T. Development of a gene therapy virus with
a glucocorticoid-inducible MMP1 for the treatment of steroid
glaucoma. Invest Ophthalmol Vis Sci. 2010;51:3029–3041.
38. Vora GJ, Lin B, Gratwick K, et al. Co-infections of adenovirus
species in previously vaccinated patients. Emerg Infect Dis.
2006;12:921–930.
39. Kontiola AI, Goldblum D, Mittag T, Danias J. The induction/
impact tonometer: a new instrument to measure intraocular
pressure in the rat. Exp Eye Res. 2001;73:781–785.
40. Danias J, Kontiola AI, Filippopoulos T, Mittag T. Method for the
noninvasive measurement of intraocular pressure in mice.
Invest Ophthalmol Vis Sci. 2003;44:1138–1141.
41. Magne D, Julien M, Vinatier C, Merhi-Soussi F, Weiss P,
Guicheux J. Cartilage formation in growth plate and arteries:
from physiology to pathology. Bioessays. 2005;27:708–716.
42. Mathieu P, Voisine P, Pepin A, Shetty R, Savard N, Dagenais F.
Calcification of human valve interstitial cells is dependent on
alkaline phosphatase activity. J Heart Valve Dis. 2005;14:353–
357.
43. Dan H, Simsa-Maziel S, Reich A, Sela-Donenfeld D, Monsonego-
Ornan E. The role of matrix gla protein in ossification and
recovery of the avian growth plate. Front Endocrinol
(Lausanne). 2012;3:79.
44. Cone FE, Steinhart MR, Oglesby EN, Kalesnykas G, Pease ME,
Quigley HA. The effects of anesthesia, mouse strain and age on
intraocular pressure and an improved murine model of
experimental glaucoma. Exp Eye Res. 2012;99:27–35.
45. Samsel PA, Kisiswa L, Erichsen JT, Cross SD, Morgan JE. A
novel method for the induction of experimental glaucoma
using magnetic microspheres. Invest Ophthalmol Vis Sci.
2011;52:1671–1675.
46. Borrás T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL.
Non-invasive observation of repeated adenoviral GFP gene
delivery to the anterior segment of the monkey eye in vivo. J
Gene Med. 2001;3:437–449.
47. Gao X, Usas A, Lu A, et al. BMP2 is superior to BMP4 for
promoting human muscle derived-stem cell mediated bone
regeneration in a critical size calvarial defect model [published
online ahead of print November 1, 2012]. Cell Transplant.
doi:10.3727/096368912X658854.
48. Zhou L, Li Y, Yue BY. Glucocorticoid effects on extracellular
matrix proteins and integrins in bovine trabecular meshwork
cells in relation to glaucoma. Int J Mol Med. 1998;1:339–346.
49. Silverio KG, Davidson KC, James RG, et al. Wnt/beta-catenin
pathway regulates bone morphogenetic protein (BMP2)-
mediated differentiation of dental follicle cells. J Periodontal
Res. 2012;47:309–319.
50. Corr M. Wnt-beta-catenin signaling in the pathogenesis of
osteoarthritis. Nat Clin Pract Rheumatol. 2008;4:550–556.
51. Chen Y, Whetstone HC, Youn A, et al. Beta-catenin signaling
pathway is crucial for bone morphogenetic protein 2 to
induce new bone formation. J Biol Chem. 2007;282:526–
533.
52. Wang WH, McNatt LG, Pang IH, et al. Increased expression of
the WNT antagonist sFRP-1 in glaucoma elevates intraocular
pressure. J Clin Invest. 2008;118:1056–1064.
53. Comes N, Borrás T. Individual molecular response to elevated
intraocular pressure in perfused postmortem human eyes.
Physiol Genomics. 2009;38:205–225.
54. Shen X, Ying H, Yue BY. Wnt activation by wild type and
mutant myocilin in cultured human trabecular meshwork
cells. PLoS One. 2012;7:e44902.
55. Kwon HS, Lee HS, Ji Y, Rubin JS, Tomarev SI. Myocilin is a
modulator of Wnt signaling. Mol Cell Biol. 2009;29:2139–
2154.
56. Shepard AR, Millar JC, Pang IH, Jacobson N, Wang WH, Clark
AF. Adenoviral gene transfer of active human transforming
growth factor-{beta}2 elevates intraocular pressure and reduc-
es outflow facility in rodent eyes. Invest Ophthalmol Vis Sci.
2010;51:2067–2076.
57. Robertson JV, Golesic E, Gauldie J, West-Mays JA. Ocular gene
transfer of active TGF-beta induces changes in anterior
segment morphology and elevated IOP in rats. Invest
Ophthalmol Vis Sci. 2010;51:308–318.
58. Junglas B, Kuespert S, Seleem AA, et al. Connective tissue
growth factor causes glaucoma by modifying the actin
cytoskeleton of the trabecular meshwork. Am J Pathol.
2012;180:2386–2403.
59. Borrás T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL.
Non-invasive observation of repeated adenoviral GFP gene
delivery to the anterior segment of the monkey eye in vivo. J
Gene Med. 2001;3:437–449.
Elevated IOP Model in Rats by Gene Transfer IOVS j August 2013 j Vol. 54 j No. 8 j 5455
